amikacin has been researched along with Critical Illness in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (10.42) | 18.2507 |
| 2000's | 7 (14.58) | 29.6817 |
| 2010's | 26 (54.17) | 24.3611 |
| 2020's | 10 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Ariza, J; Dominguez, MA; Gudiol, F; Guzmán, A; Peña, C; Pujol, M; Suarez, C; Tubau, F | 1 |
| Ghaffari, S; Hadi, AM; Mojtahedzadeh, M; Najafi, A; Najmeddin, F; Rouini, MR; Shahrami, B | 1 |
| Arabzadeh, AA; Khezrnia, SS; Mojtahedzadeh, M; Najafi, A; Najmeddin, F; Rouini, MR; Sefidani Forough, A; Shahrami, B | 1 |
| Duong, A; Marsot, A; Simard, C; Thirion, DJG; Williamson, D | 1 |
| Cömert, B; Ergan, B; Ergün, B; Esenkaya, F; Gökmen, AN; Hanci, V; Heybeli, C; Küçük, M; Uzun, Ö; Yakar, MN | 1 |
| Li, S; Xie, F; Zhu, S | 1 |
| Caruso, P; de Lima Moreira, F; de Souza Borges, O; Diegues, MS; E Silva, ILF; Gavazza, BV; Migotto, KC; Pinto, L; Reghini, R; Schmidt, S; Telles, JP | 1 |
| Adeleke, G; Egbagbe, E; Ejembi, J; Ettu, AO; Habib, A; Irowa, OO; Makanjuola, OB; Medugu, N; Mutiu, B; Ogunbosi, B; Ogunsola, F; Oladele, RO; Osinaike, T; Rotimi, V; Uwaezuoke, NS | 1 |
| Andreu, P; Azaïs, MA; Barbier, F; Beduneau, G; Benzekri, D; Chebib, N; Clere-Jehl, R; Dahyot-Fizelier, C; Demiselle, J; Ehrmann, S; Ferrandiere, M; Gandonnière, CS; Garot, D; Gouin, P; Gregoire, N; Herbrecht, JE; Heuzé-Vourc'h, N; Lacherade, JC; Landais, M; Lasocki, S; Lu, Q; Mercier, E; Merdji, H; Meziani, F; Nay, MA; Plantefève, G; Quenot, JP; Respaud, R; Roux, D; Saint-Martin, M; Schnell, D; Seguin, P; Tavernier, E; Veinstein, A; Zucman, N | 1 |
| Annaert, P; De Winter, S; Desmet, S; Dreesen, E; Meersseman, W; Peetermans, W; Spriet, I; Van den Eede, N; van Hest, R; Vanbrabant, P; Verelst, S; Wauters, J | 1 |
| Bulitta, JB; Klee, BO; Zavascki, AP | 1 |
| Cikánková, T; Hartinger, J; Šíma, M; Slanař, O | 1 |
| Broch, MJ; Castellanos-Ortega, Á; Gordon, M; Martin-Cerezula, M; Poveda, JL; Ramírez, P; Remedios Marqués, M; Ruiz-Ramos, J; Villarreal, E | 1 |
| Ahmadi, A; Azadbakht, S; Dianatkhah, M; Mojtahedzadeh, M; Najafi, A; Najmeddin, F; Rouini, MR; Shahrami, B; Sharifnia, H | 1 |
| Han, YK; Kang, T; Kim, DH; Kim, DJ; Kim, SW; Lee, DH; Lee, J; Yu, H | 1 |
| Ahmadi, A; Mahmoudi, L; Mohammadpour, AH; Mojtahedzadeh, M; Niknam, R | 1 |
| Abdul-Malek, K; Al-lanqawi, Y; Jelliffe, R; Matar, KM | 1 |
| Lanao, JM; Martín-Suárez, A; Zazo, H | 1 |
| Duszynska, W; Hurkacz, M; Kowalska-Krochmal, B; Kübler, A; Taccone, FS; Wiela-Hojeńska, A | 1 |
| Ahmadi, A; Mahmoudi, L; Mohammadpour, AH; Mojtahedzdeh, M; Niknam, R | 1 |
| Bouadma, L; Chemam, S; de Montmollin, E; Gault, N; Mariotte, E; Massias, L; Mourvillier, B; Papy, E; Sonneville, R; Tubach, F; Wolff, M | 1 |
| Ahmadi, A; Ahmadvand, A; Khalili, H; Mahmoudi, L; Mojtahedzadeh, M; Najafi, A; Najmeddin, F; Sadeghi, K | 1 |
| Armand-Lefèvre, L; Burdet, C; Couffignal, C; Foucrier, A; Laouénan, C; Massias, L; Mentré, F; Pajot, O; Wolff, M | 1 |
| Bursle, E; Cotta, MO; Gowen, B; Lipman, J; McWhinney, B; Roberts, JA; Truloff, N; Ungerer, JP | 1 |
| Aubert, C; Barbar, S; Bastide, S; Elotmani, L; Lefrant, JY; Lloret, S; Molinari, N; Muller, L; Nucci, B; Polge, A; Pradel, G; Roberts, JA; Roger, C; Saissi, G | 1 |
| Allaouchiche, B; Evrard, A; Friggeri, A; Knani, H; Lavigne, JP; Lefrant, JY; Louart, B; Muller, L; Nucci, B; Roberts, JA; Roger, C | 1 |
| Bouadma, L; de Montmollin, E; Gélisse, E; Mourvillier, B; Neuville, M; Sonneville, R; Timsit, JF | 1 |
| Lefrant, JY; Lipman, J; Muller, L; Roberts, JA; Roger, C; Saissi, G; Wallis, SC | 1 |
| Blin, O; Guilhaumou, R; Marsot, A; Riff, C | 1 |
| Boulain, T; Darrouzain, F; Dequin, PF; Ehrmann, S; Garot, D; Paintaud, G; Petitcollin, A; Ternant, D; Vecellio, L | 1 |
| Glikman, D; Hoffmann, Y; Kassem, DF; Ocampo, S; Salomon, L; Shahar, N; Zonis, Z | 1 |
| Ardanuy, R; Domínguez-Gil, A; Lanao, JM; Mar Fernández de Gatta, MD; Moreno, SR; Victoria Calvo, M | 1 |
| Boucher, BA; Croce, MA; Czosnowski, QA; Fabian, TC; Magnotti, LJ; Swanson, JM; Wood, GC | 1 |
| Cumps, J; Delattre, IK; Dugernier, T; Jacobs, F; Laterre, PF; Musuamba, FT; Spapen, H; Taccone, FS; Verbeeck, RK; Vincent, JL; Wallemacq, PE; Wittebole, X | 1 |
| Delattre, IK; Jacobs, F; Laterre, PF; Musuamba, FT; Nyberg, J; Taccone, FS; Verbeeck, RK; Wallemacq, PE | 1 |
| Chastre, J; Corkery, K; Eldon, MA; Gribben, D; Luyt, CE; Stass, H | 1 |
| Fujita, T; Hanafusa, N; Hisaka, A; Katada, S; Noiri, E; Suzuki, H; Yahagi, N; Yamamoto, T; Yasuno, N | 1 |
| Delattre, IK; Jacobs, F; Jacqmin, P; Laterre, PF; Musuamba, FT; Taccone, FS; Verbeeck, RK; Wallemacq, P | 1 |
| Casey, E; Corrigan, OI; D'Arcy, DM; Donnelly, MB; Gowing, CM | 1 |
| Archambaud, M; Chabanon, G; Conil, JM; Cougot, P; Decun, JF; Georges, B; Houin, G; Saivin, S; Seguin, T; Virenque, C | 1 |
| Gündeş, S; Solak, M; Toker, K; Willke, A; Yildiz, T | 1 |
| Cicek, A; Durmaz, R; Kuzucu, C; Otlu, B; Yetkin, G | 1 |
| Abelha, F; Menezes, MR; Pimentel, FL; Sá, LV; Trigo, MA | 1 |
| Marik, PE | 1 |
| Bressolle, F; Gomeni, R; Gouby, A; Guillaud, R; Joubert, P; Martinez, JM; Saissi, G | 1 |
| Abu-Aisha, H; al-Zeer, AH; Dahmash, NS; Fayed, DF; Huraib, SO; Shibl, AM | 1 |
| Castañeda-Hernández, G; Lugo, G | 1 |
| Castañeda-Hernández, G; Lugo-Goytia, G | 1 |
2 review(s) available for amikacin and Critical Illness
| Article | Year |
|---|---|
Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
Topics: Amikacin; Anti-Bacterial Agents; Biological Availability; Carbapenem-Resistant Enterobacteriaceae; Cell Membrane Permeability; Critical Illness; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae Infections; Gentamicins; Humans; Microbial Sensitivity Tests; Protein Biosynthesis | 2017 |
Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.
Topics: Amikacin; Anti-Bacterial Agents; Clinical Trials as Topic; Critical Illness; Female; Humans; Male | 2017 |
14 trial(s) available for amikacin and Critical Illness
| Article | Year |
|---|---|
Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia.
Topics: Administration, Inhalation; Adult; Amikacin; Anti-Bacterial Agents; Critical Illness; Double-Blind Method; Humans; Pneumonia, Ventilator-Associated; Respiration, Artificial; Treatment Outcome | 2023 |
Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
Topics: Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critical Illness; Dose-Response Relationship, Drug; Emergency Service, Hospital; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Prospective Studies; Sepsis; Shock, Septic; Tissue Distribution | 2021 |
Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients.
Topics: Aged; Amikacin; Critical Illness; Female; Hemodiafiltration; Humans; Male; Middle Aged | 2018 |
Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
Topics: Adult; Amikacin; Anti-Bacterial Agents; APACHE; Creatinine; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gram-Negative Bacterial Infections; Hemodynamics; Humans; Intensive Care Units; Male; Middle Aged; Models, Biological; Sepsis; Severity of Illness Index; Tissue Distribution | 2013 |
Amikacin population pharmacokinetics in critically ill Kuwaiti patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amikacin; Anti-Bacterial Agents; Arabs; Critical Illness; Female; Humans; Kuwait; Male; Middle Aged; Models, Biological | 2013 |
Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Sepsis; Single-Blind Method | 2014 |
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Pneumonia, Ventilator-Associated | 2015 |
Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; Hemodiafiltration; Hemofiltration; Humans; Kidney; Male; Metabolic Clearance Rate; Monte Carlo Method; Renal Replacement Therapy | 2016 |
Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
Topics: Acute Kidney Injury; Aerosols; Aged; Amikacin; Anti-Bacterial Agents; Area Under Curve; Critical Illness; Drug Delivery Systems; Female; Follow-Up Studies; Gram-Negative Bacterial Infections; Hemodiafiltration; Humans; Male; Middle Aged; Pneumonia, Bacterial; Respiration, Artificial; Tissue Distribution | 2011 |
Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Critical Illness; Drug Monitoring; Female; Humans; Male; Meropenem; Metabolic Clearance Rate; Middle Aged; Models, Biological; Piperacillin; Sepsis; Thienamycins; Tissue Distribution; Treatment Outcome | 2012 |
An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; Hemodiafiltration; Humans; Male; Middle Aged; Models, Biological; Prospective Studies | 2012 |
Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Area Under Curve; Cefepime; Cephalosporins; Critical Illness; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome | 2005 |
Population pharmacokinetics of amikacin in critically ill patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Bayes Theorem; Body Fluid Compartments; Child; Child, Preschool; Critical Illness; Female; Humans; Infant; Male; Middle Aged; Predictive Value of Tests | 1996 |
Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis.
Topics: Amikacin; Anti-Bacterial Agents; Bayes Theorem; Critical Illness; Humans; Liver Cirrhosis; Middle Aged; Sepsis | 1997 |
32 other study(ies) available for amikacin and Critical Illness
| Article | Year |
|---|---|
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Critical Illness; Endemic Diseases; Female; Gastrointestinal Tract; Humans; Imipenem; Incidence; Intensive Care Units; Male; Middle Aged; Pharynx; Pseudomonas aeruginosa; Pseudomonas Infections; Rectum; Risk Factors | 2007 |
Evaluation of amikacin dosing schedule in critically ill elderly patients with different stages of renal dysfunction.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Critical Illness; Half-Life; Humans; Kidney Diseases; Middle Aged | 2022 |
Relationship between amikacin pharmacokinetics and biological parameters associated with organ dysfunction: a case series study of critically ill patients with intra-abdominal sepsis.
Topics: Amikacin; Anti-Bacterial Agents; Critical Illness; Humans; Multiple Organ Failure; Sepsis | 2022 |
Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Critical Illness; Drug Monitoring; Gentamicins; Hospitals; Humans; Quebec; Tobramycin | 2022 |
Amikacin-induced acute kidney injury in mechanically ventilated critically ill patients with sepsis.
Topics: Acute Kidney Injury; Amikacin; Colistin; Critical Illness; Humans; Intensive Care Units; Respiration, Artificial; Retrospective Studies; Risk Factors; Sepsis; Shock, Septic | 2023 |
Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration.
Topics: Amikacin; Anti-Bacterial Agents; Continuous Renal Replacement Therapy; Critical Illness; Hemodiafiltration; Humans; Microbial Sensitivity Tests | 2023 |
Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: applying PBPK approach in a therapeutic drug monitoring study.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Critical Illness; Drug Monitoring; Glomerular Filtration Rate; Humans; Neoplasms | 2023 |
Antibiotic Guidelines for Critically Ill Patients in Nigeria.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Clavulanic Acid; Community-Acquired Infections; Critical Illness; Cross Infection; Fluconazole; Humans; Meropenem; Microbial Sensitivity Tests; Nigeria; Piperacillin, Tazobactam Drug Combination; Pneumonia; Prospective Studies; Urinary Tract Infections | 2023 |
Estimation of once-daily amikacin dose in critically ill adults.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged | 2018 |
Evaluation of Epithelial Lining Fluid Concentration of Amikacin in Critically Ill Patients With Ventilator-Associated Pneumonia.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Critical Illness; Female; Humans; Lung; Male; Middle Aged; Pilot Projects; Pneumonia, Ventilator-Associated; Pulmonary Alveoli; Respiratory Mucosa | 2020 |
Nephrotoxicity of amikacin in noncritically ill patients
.
Topics: Acute Kidney Injury; Adult; Aged; Amikacin; Anti-Bacterial Agents; Critical Illness; Drug Monitoring; Female; Humans; Male; Middle Aged; Retrospective Studies | 2019 |
Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Critical Illness; Humans; Intensive Care Units; Microbial Sensitivity Tests; Models, Statistical; Plasma; Time Factors | 2013 |
Therapeutic drug monitoring of amikacin in septic patients.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Sepsis | 2013 |
Limited sampling strategy for estimation of amikacin optimal sampling time in critically ill adults.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Area Under Curve; Cost-Benefit Analysis; Critical Illness; Female; Humans; Male; Middle Aged; Prospective Studies; Specimen Handling; Time Factors | 2014 |
Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Body Mass Index; Body Weight; Critical Illness; Dose-Response Relationship, Drug; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Injections; Intensive Care Units; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Risk Factors | 2014 |
Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Bacterial; Female; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Thienamycins | 2015 |
Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Cohort Studies; Critical Illness; Female; Gentamicins; Humans; Intraabdominal Infections; Male; Middle Aged; Plasma; Pneumonia, Bacterial; Urinary Tract Infections | 2015 |
Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; France; Gentamicins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Sepsis; Serum; Young Adult | 2016 |
Extracorporeal membrane oxygenation (ECMO) does not impact on amikacin pharmacokinetics: a case-control study.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Male; Middle Aged; Treatment Outcome | 2016 |
Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients.
Topics: Adult; Aerosols; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; Humans; Male; Middle Aged; Pneumonia, Ventilator-Associated; Respiration, Artificial; Serum; Young Adult | 2016 |
Multidrug-Resistant Pathogens in Hospitalized Syrian Children.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Armed Conflicts; Bacterial Infections; Child; Child, Preschool; Colistin; Critical Illness; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; Infant; Infant, Newborn; Israel; Male; Meropenem; Multiple Trauma; Syria; Thienamycins | 2017 |
Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
Topics: Amikacin; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Bayes Theorem; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Hospitals, University; Humans; Intensive Care Units; Male; Middle Aged; Models, Statistical; Predictive Value of Tests; Retrospective Studies | 2009 |
Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia.
Topics: Acinetobacter baumannii; Adult; Aerosols; Amikacin; Anti-Bacterial Agents; APACHE; Colistin; Critical Illness; Drug Resistance, Multiple; Female; Glasgow Coma Scale; Gram-Negative Bacteria; Humans; Male; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Retrospective Studies; Tobramycin; Treatment Outcome | 2009 |
Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactams; Calibration; Critical Illness; Drug Dosage Calculations; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Empirical Research; Female; Humans; Male; Middle Aged; Models, Theoretical; Sepsis; Young Adult | 2010 |
Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bayes Theorem; Creatinine; Critical Illness; Drug Monitoring; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Sepsis; Tissue Distribution | 2010 |
Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemodiafiltration; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nomograms; Teicoplanin; Vancomycin; Young Adult | 2011 |
Spontaneous, nontraumatic gas gangrene due to Clostridium perfringens.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Blister; Ceftazidime; Clostridium perfringens; Critical Illness; Fatal Outcome; Gas Gangrene; Humans; Injections, Intravenous; Male; Metronidazole; Middle Aged; Stomatitis, Aphthous | 2006 |
Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
Topics: Amikacin; Anti-Bacterial Agents; Critical Illness; Cross Infection; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Female; Hospitals, University; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Molecular Epidemiology; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; Turkey | 2006 |
Determination of plasma concentrations of amikacin in patients of an intensive care unit.
Topics: Adult; Amikacin; Aminoglycosides; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Intensive Care Units; Male; Middle Aged | 1995 |
Aminoglycoside volume of distribution and illness severity in critically ill septic patients.
Topics: Adult; Amikacin; Creatinine; Critical Illness; Extracellular Space; Gram-Negative Bacterial Infections; Humans; Sepsis; Severity of Illness Index | 1993 |
Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; APACHE; Ceftazidime; Critical Illness; Drug Administration Schedule; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged | 1996 |
Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis.
Topics: Amikacin; Anti-Bacterial Agents; Bayes Theorem; Critical Care; Critical Illness; Humans; Middle Aged; Models, Statistical; Retrospective Studies; Sepsis | 2000 |